Literature DB >> 1323799

Selective venous sampling in the differential diagnosis of ACTH-dependent Cushing's syndrome.

M Boscaro1, A Rampazzo, A Paoletta, P Roseano, U Pagotto, F Fallo, N Sonino.   

Abstract

Bilateral simultaneous inferior petrosal sinus sampling, associated with the oCRH stimulation test (100 micrograms i.v. as a bolus) was performed in 22 patients with Cushing's syndrome and no signs of pituitary abnormalities. Catheters were inserted into both femoral veins. More than one site in the superior and inferior vena cava was sampled before reaching the inferior petrosal sinuses. Blood samples for ACTH and beta-endorphin were gently aspirated from both petrosal sinuses and from a peripheral vein simultaneously. Blood was drawn at 0, 5, 10 and 15 min after oCRH injection. Seventeen of 22 patients showed an ipsilateral to peripheral vein ratio higher than 1.5, and 12 patients showed a lateralization of ACTH levels after oCRH stimulation. Seventeen patients underwent transsphenoidal pituitary surgery. Nine patients had a pituitary adenoma at the expected side; 1 at the contralateral side, while in 2 it was central. Three of 4 patients in whom the ipsilateral/peripheral ratio was less than 1.5 had the highest ACTH levels at the superior or inferior vena cava, not responsive to oCRH stimulation. One of these had a mediastinal and one a pulmonary mass. The third one, with an occult ectopic source, is still under investigation. At immunohistochemical and biological in vitro studies, both tumors were shown to secrete ACTH. In 13 patients in whom both beta-endorphin and ACTH measurements were performed, these hormones showed similar patterns of response. In conclusion, simultaneous bilateral petrosal sinus catheterization is a useful tool in the differential diagnosis of Cushing's syndrome as concerning pituitary and ectopic forms.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1323799     DOI: 10.1159/000126124

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  7 in total

Review 1.  Inferior petrosal sinus sampling in Cushing's syndrome: usefulness and pitfalls.

Authors:  D A Vassiliadi; P Mourelatos; T Kratimenos; S Tsagarakis
Journal:  Endocrine       Date:  2021-06-02       Impact factor: 3.633

2.  Selective use of bilateral inferior petrosal sinus sampling in patients with adrenocorticotropin-dependent Cushing's syndrome prior to transsphenoidal surgery.

Authors:  Sigrid Jehle; Jane E Walsh; Pamela U Freda; Kalmon D Post
Journal:  J Clin Endocrinol Metab       Date:  2008-09-16       Impact factor: 5.958

3.  Adrenocorticotropic hormone-dependent Cushing's syndrome: sensitivity and specificity of inferior petrosal sinus sampling.

Authors:  F S Bonelli; J Huston; P C Carpenter; D Erickson; W F Young; F B Meyer
Journal:  AJNR Am J Neuroradiol       Date:  2000-04       Impact factor: 3.825

4.  Effect of the serotonin antagonists ritanserin and ketanserin in Cushing's disease.

Authors:  N Sonino; G A Fava; F Fallo; A Franceschetto; P Belluardo; M Boscaro
Journal:  Pituitary       Date:  2000-10       Impact factor: 4.107

5.  Role of bilateral adrenalectomy in Cushing's disease.

Authors:  G Favia; M Boscaro; F Lumachi; D F D'Amico
Journal:  World J Surg       Date:  1994 Jul-Aug       Impact factor: 3.352

6.  Corticotropin-releasing hormone test: improvement of the diagnostic accuracy of simultaneous and bilateral inferior petrosal sinus sampling in patients with Cushing syndrome.

Authors:  L Zarrilli; A Colao; B Merola; G La Tessa; R Spaziante; F S Tripodi; A Di Sarno; L A Marzano; G Lombardi
Journal:  World J Surg       Date:  1995 Jan-Feb       Impact factor: 3.352

7.  Diagnostic accuracy and comparison of BIPSS in response to lysine vasopressin and hCRH.

Authors:  Kush Dev Singh Jarial; Anil Bhansali; Vivek Gupta; Paramjeet Singh; Kanchan K Mukherjee; Akhilesh Sharma; Rakesh K Vashishtha; Suja P Sukumar; Naresh Sachdeva; Rama Walia
Journal:  Endocr Connect       Date:  2018-02-12       Impact factor: 3.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.